Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth …